Abstract:Aim: Retinoic acid receptor-related orphan nuclear receptors (RORs) are orphan nuclear receptors that show constitutive activity in the absence of ligands. Among 3 subtypes of RORs, RORc is a promising therapeutic target for the treatment of Th17-mediated autoimmune diseases. Here, we report novel RORc inverse agonists discovered through structure-based drug design. Methods: Based on the structure of compound 8, a previously described agonist of RORa, a series of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives were designed and synthesized. The interaction between the compounds and RORc was detected at molecular level using AlphaScreen assay. The compounds were further examined in 293T cells transfected with RORc and luciferase reporter gene. Thermal stability shift assay was used to evaluate the effects of the compounds on protein stability. Results: A total of 27 derivatives were designed and synthesized. Among them, the compound 22b was identified as the most potent RORc inverse agonist. Its IC 50 values were 2.39 μmol/L in AlphaScreen assay, and 0.82 μmol/L in inhibition of the cell-based luciferase reporter activity. Furthermore, the compound 22b displayed a 120-fold selectivity for RORc over other nuclear receptors. Moreover, a molecular docking study showed that the structure-activity relationship was consistent with the binding mode of compound 22b in RORc. Conclusion: 4-(4-(Benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives are promising candidates for the treatment of Th17-mediated autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties

Structure-guided design of a highly potent RXR agonist with superior physicochemical properties

Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist Potency

Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

A Structure-based Approach to Retinoid X Receptor-α Inhibition

Structural optimization of oxaprozin for selective inverse Nurr1 agonism

Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor

Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor

Structural basis for the full and partial agonist activities of retinoid X receptor α ligands with an iso-butoxy and an isopropyl group

Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.

Structure-guided Modification of Isoxazole-Type FXR Agonists: Identification of a Potent and Orally Bioavailable FXR Modulator

Retinoid X receptor ligands: a patent review (2007 – 2013)

Discovery and Structural Optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1h)-ones As RORc Inverse Agonists

Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB)

Determinants of retinoid X receptor transcriptional antagonism.

Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.

A review of the molecular design and biological activities of RXR agonists

Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.